Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab in episodic migraine (PERSIST)
NCT03963232Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of galcanezumab in episodic migraine, sponsored by Eli Lilly and Company. Started Jul 2019; status: completed.
02
Drugs
galcanezumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT03963232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03963232.